Breast cancer chemoprevention: Progress and controversy

Surgical Oncology Clinics of North America

Volumn 19, Issue 3, 2010, Pages 463-473

  Wickerham, D Lawrence ^a,b,c  

^a NSABP Foundation Inc   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemoprevention; Raloxifene; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; EXEMESTANE; LASOFOXIFENE; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ALCOHOL CONSUMPTION; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER INCIDENCE; CANCER RISK; CATARACT; CATARACT EXTRACTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRINKING BEHAVIOR; DRUG APPROVAL; DRUG DOSE COMPARISON; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EXERCISE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INTRADUCTAL CARCINOMA; LIFESTYLE MODIFICATION; LOW FAT DIET; LUNG EMBOLISM; MASTECTOMY; MEDICAL DECISION MAKING; OSTEOPOROSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UTERUS DISEASE; WEIGHT REDUCTION; BREAST TUMOR; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 77954163655     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.03.005     Document Type: Review

References (28)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77-84.
3. Hong W.K., Sporn M.B. Recent advances in chemoprevention of cancer. Science 1997, 278:1073-1077.
4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
5. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371-1378.
6. Fisher B., Costantino J., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
7. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP P-1) breast cancer prevention trial. JAMA 2001, 286:2251-2256.
8. Narod S.A., Brunet J.S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000, 356:1876-1881.
9. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
10. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
11. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98-101.
12. Powles T.J., Ashley S., Tidy A., et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283-290.
13. Veronesi U., Maisonneuve P., Rotmensz N., et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003, 95:160-165.
14. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.
15. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189-2197.
16. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
17. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
18. LaCroix A.Z., Cummings S.R., Delmas P., et al. Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women. Cancer Res 2009, 69:11. [abstract 11]. San Antonio Breast Cancer Symposium. San Antonio (TX), December 11, 2008, General Session I.
19. Powles T, Diem S, Wickerham L, et al. Effects of arzoxifene on breast cancer incidence in postmenopausal women with osteoporosis or with low bone mass [abstract 51]. San Antonio Breast Cancer Symposium. San Antonio (TX), December 11, 2009, General Session IV.
20. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001, 19:881-894.
21. Thüerlimann B. Adjuvant hormonal therapy for breast cancer: an evolving process (archived web conference) Presented at Primary Therapy of Early Breast Cancer 9th International Conference. St Gallen (Switzerland), January 26-29, 2005. Available at:, Accessed February 12, 2010. http://www.medscape.com/viewprogram/3800_pnt.
22. Jakesz R., on behalf of the ABCSG and the GABG Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial [abstract 2]. Breast Cancer Res Treat 2004, 88(Suppl 1):S1-265. San Antonio Breast Cancer Symposium. San Antonio (TX), December 8-11, 2004.
23. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
24. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
25. Baum M., Buzdar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
26. Visvanathan K., Chlebowski R.T., Hurley P., et al. American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009, 27:3235-3258.
27. Chlebowski R.T., Collyar D.E., Somerfield M.R., et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999, 17:1939-1955.
28. Chelbowski R.T., Col N., Winer E.P., et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002, 20:3328-3343.